WO2009109991A3 - Novel hydrazide containing tyrosine kinase inhibitors - Google Patents

Novel hydrazide containing tyrosine kinase inhibitors Download PDF

Info

Publication number
WO2009109991A3
WO2009109991A3 PCT/IN2009/000057 IN2009000057W WO2009109991A3 WO 2009109991 A3 WO2009109991 A3 WO 2009109991A3 IN 2009000057 W IN2009000057 W IN 2009000057W WO 2009109991 A3 WO2009109991 A3 WO 2009109991A3
Authority
WO
WIPO (PCT)
Prior art keywords
tyrosine kinase
kinase inhibitors
containing tyrosine
hydrazide containing
novel hydrazide
Prior art date
Application number
PCT/IN2009/000057
Other languages
French (fr)
Other versions
WO2009109991A2 (en
Inventor
Prabal Sengupta
Chetan Surjitsingh Puri
Hemantkumar Chokshi
Trinadha Rao Chitturi
Rajamannar Thennati
Original Assignee
Sun Pharma Advanced Research Company Ltd.,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharma Advanced Research Company Ltd., filed Critical Sun Pharma Advanced Research Company Ltd.,
Publication of WO2009109991A2 publication Critical patent/WO2009109991A2/en
Publication of WO2009109991A3 publication Critical patent/WO2009109991A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

The present invention relates to compounds of formula (I), and salts thereof, wherein P represents a 5 or 6-membered heteroaryl ring; R1 is aryl or unsaturated heterocyclyl radical optionally substituted by one or more identical or different radicals R5.
PCT/IN2009/000057 2008-01-23 2009-01-22 Novel hydrazide containing tyrosine kinase inhibitors WO2009109991A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN160MU2008 2008-01-23
IN160/MUM/2008 2008-01-23

Publications (2)

Publication Number Publication Date
WO2009109991A2 WO2009109991A2 (en) 2009-09-11
WO2009109991A3 true WO2009109991A3 (en) 2010-11-25

Family

ID=41056431

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2009/000057 WO2009109991A2 (en) 2008-01-23 2009-01-22 Novel hydrazide containing tyrosine kinase inhibitors

Country Status (1)

Country Link
WO (1) WO2009109991A2 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2361242B1 (en) 2008-10-17 2018-08-01 Oryzon Genomics, S.A. Oxidase inhibitors and their use
WO2010084160A1 (en) 2009-01-21 2010-07-29 Oryzon Genomics S.A. Phenylcyclopropylamine derivatives and their medical use
MX338041B (en) 2009-09-25 2016-03-30 Oryzon Genomics Sa Lysine specific demethylase-1 inhibitors and their use.
EP2486002B1 (en) 2009-10-09 2019-03-27 Oryzon Genomics, S.A. Substituted heteroaryl- and aryl- cyclopropylamine acetamides and their use
US9616058B2 (en) 2010-02-24 2017-04-11 Oryzon Genomics, S.A. Potent selective LSD1 inhibitors and dual LSD1/MAO-B inhibitors for antiviral use
US9186337B2 (en) 2010-02-24 2015-11-17 Oryzon Genomics S.A. Lysine demethylase inhibitors for diseases and disorders associated with Hepadnaviridae
MX2012012111A (en) 2010-04-19 2013-05-30 Oryzon Genomics Sa Lysine specific demethylase-1 inhibitors and their use.
US9006449B2 (en) 2010-07-29 2015-04-14 Oryzon Genomics, S.A. Cyclopropylamine derivatives useful as LSD1 inhibitors
RS57331B1 (en) 2010-07-29 2018-08-31 Oryzon Genomics Sa Arylcyclopropylamine based demethylase inhibitors of lsd1 and their medical use
US9061966B2 (en) 2010-10-08 2015-06-23 Oryzon Genomics S.A. Cyclopropylamine inhibitors of oxidases
WO2012072713A2 (en) 2010-11-30 2012-06-07 Oryzon Genomics, S.A. Lysine demethylase inhibitors for diseases and disorders associated with flaviviridae
EP2712316A1 (en) * 2011-02-08 2014-04-02 Oryzon Genomics, S.A. Lysine demethylase inhibitors for myeloproliferative or lymphoproliferative diseases or disorders
EP3981395A1 (en) 2011-02-08 2022-04-13 Oryzon Genomics, S.A. Lysine demethylase inhibitors for myeloproliferative disorders
PE20141692A1 (en) 2011-10-20 2014-11-08 Oryzon Genomics Sa (HETERO) ARYL CYCLOPROPYLAMINE COMPOUNDS AS INHIBITORS OF LSD1
CN107266345B (en) 2011-10-20 2021-08-17 奥瑞泽恩基因组学股份有限公司 (hetero) arylcyclopropylamine compounds as LSD1 inhibitors
US9061028B2 (en) 2012-02-15 2015-06-23 Natco Pharma Limited Process for the preparation of Nilotinib
CN104945388A (en) * 2015-07-09 2015-09-30 南京大学 Preparing method for 4-(3-(3-(4-clocoumarol)-acylhydrazone)-5-phenyl-pyrazol) benzene sulfonamide derivate and application to anti-cancer drugs
CN107056713A (en) * 2017-05-18 2017-08-18 厦门大学 4 ((pyrimidine radicals of 4 substituted aryl 2) amino) benzoyl hydrazine derivatives and its preparation method and application
CN113975271B (en) * 2021-09-02 2022-06-21 苏州大学附属第一医院 Application of small molecular compound in preparation of medicine for treating tumors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002083654A1 (en) * 2001-04-11 2002-10-24 Amgen Inc. Triazinyl amide derivatives as angiogenesis inhibitors
WO2006133426A2 (en) * 2005-06-08 2006-12-14 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002083654A1 (en) * 2001-04-11 2002-10-24 Amgen Inc. Triazinyl amide derivatives as angiogenesis inhibitors
WO2006133426A2 (en) * 2005-06-08 2006-12-14 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway

Also Published As

Publication number Publication date
WO2009109991A2 (en) 2009-09-11

Similar Documents

Publication Publication Date Title
WO2009109991A3 (en) Novel hydrazide containing tyrosine kinase inhibitors
WO2007105058A8 (en) Pyrazole compounds
NO20060145L (en) Substituted indazolyl (indolyl) maleimide derivatives as kinase inhibitors
TW200633991A (en) Chemical compounds
NO20063780L (en) Process for the preparation of 2-aminithiazole-5-aromatic carboxamide as kinase inhibitors.
EA201100189A1 (en) Heteroaryl Derivatives As DGAT1 Inhibitors
NO20092692L (en) MAPK / ERK kinase inhibitors
MX2012002752A (en) Heteroaryl compounds as kinase inhibitors.
WO2008039359A3 (en) Bicyclic pyrimidine kinase inhibitors
MD4582C1 (en) 1-Phenyl-1H-benzimidazole derivatives as protein kinase inhibitors
NO20091141L (en) Pyrido (2,3-D) pyrimidinone compounds and their use as P13 inhibitors
RS54199B1 (en) Process for preparing intermediates of compounds useful as opioid receptor modulators
TN2011000274A1 (en) Carbazole carboxamide compounds useful as kinase inhibitors
WO2010014930A3 (en) Piperidine derivatives as jak3 inhibitors
WO2012080284A3 (en) Substituted 6,6-fused nitrogenous heterocyclic compounds and uses thereof
EA201000113A1 (en) PYRAZOL COMPOUNDS
NO20085107L (en) Spirocyclic nitriles as protease inhibitors
EA201000101A1 (en) DERIVATIVES OF PYRIMIDINE 934
WO2008036967A3 (en) Novel heterocyclic compounds as lasy activators
NO20081206L (en) Isoquinolines derivatives as IGF -1R inhibitors
EA201200891A1 (en) DERIVATIVES 3,4,4A, 10D-TETRAGIDRO-1H-TIOPIRANO [4,3-C] IZOHINOLINA
DK2197860T3 (en) Novel compounds as adenosine A1 receptor antagonists
MX2019013979A (en) Methods for the preparation of 1,3-benzodioxole heterocyclic compounds.
EA200801549A1 (en) NEW PENANTRIDINE DERIVATIVES AS ANTAGONISTS OF BRADIKININ
WO2006031929A3 (en) Thiazolopyridine kinase inhibitors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09718021

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09718021

Country of ref document: EP

Kind code of ref document: A2